Reistone Biopharma Funding: $100M Raised, Series A (2022)
Reistone Biopharma is based in Shanghai, China. It has raised $100M in total funding. Latest round: Series A.
Reistone Biopharma funding overview
Reistone Biopharma is based in Shanghai, China. Reistone Biopharma has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in May 2022. The round record for Reistone Biopharma runs through 2022; nothing later has been disclosed. Investors on record include Huagai Capital, Shanghai Shengdi Pharmaceutical. 2 distinct backers are named across the disclosed rounds.
Reistone Biopharma at a glance
Total raised
$100M
Latest round
Series A
Latest round date
May 2022
Headquarters
Shanghai, China
Notable investors
Huagai Capital, Shanghai Shengdi Pharmaceutical
Frequently asked about Reistone Biopharma funding
How much has Reistone Biopharma raised?
Reistone Biopharma has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Reistone Biopharma?
Huagai Capital, Shanghai Shengdi Pharmaceutical are named among the investors backing Reistone Biopharma.
What was the latest Reistone Biopharma funding round?
The most recent disclosed round is a Series A, announced in May 2022.
Where is Reistone Biopharma based?
Reistone Biopharma is based in Shanghai, China.
When did Reistone Biopharma last raise?
The last disclosed Reistone Biopharma round closed in May 2022 at Series A.
Totals shown for Reistone Biopharma aggregate every disclosed round on file. To see how that compares, browse the companies in Shanghai and the investors behind them below.
